Mobius Therapeutics, LLC
The only FDA approved formulation of mitomycin-c with an ophthalmic indication. Orphan drug status. Patent exclusivity until 2029.
Mobius has developed a patent protected system, Mitosol®, for delivering mitomycin-c in glaucoma, refractive, and pterygium surgeries. Mobius gained FDA approval in 2012 for glaucoma and is pursuing additional indications. Mitosol® enhances OR safety and is stored at room temperature; shelf life grows from 14 days to 2 years vs compounding. Potency is assured and technique is unchanged. Mitosol is reimbursed whereas compounded MMC is not.